Mayara Torquato Lima da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mayara Torquato Lima da Silva has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Carolaine da Silva
Laboratório de Síntese de Heterociclos, Instituto de Química, Departamento de Química Orgânica, Universidade Federal Fluminense, Niterói, RJ, Brasil., Brazil
1 shared publication - Clara de Paulo Lima
Laboratório de Biotecnologia e Bioengenharia Estrutural, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil., Brazil
1 shared publication - Diego Allonso
Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
1 shared publication - Flaviana Rodrigues Fintelman Dias
Laboratório de Síntese de Moléculas Orgânicas, Instituto de Química, Departamento de Química Orgânica, Universidade Federal Fluminense, Niterói, RJ, Brasil., Brazil
1 shared publication - Luiz Carlos da Silva Pinheiro
Faculdade de Formação de Professores, Departamento de Ciências, Universidade do Estado do Rio de Janeiro—UERJ, São Gonçalo 24435-005, RJ, Brazil
1 shared publication - Ronaldo Mohana-Borges
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 20 January 2026
- Published by MDPI AG in Preprints.org
Hydrazone-Isatin Derivatives as Antivirals Against Chikungunya Virus: Insights From Biological and Computational Studies
Chikungunya virus (CHIKV), a re-emerging arbovirus of the Alphavirus genus, causes acute febrile illness often followed by persistent polyarthritis or arthralgia. Due to its rapid transmission and the absence of approved antivirals or licensed vaccines, there is an urgent need for effective therapeutic strategies. Among potential antiviral targets, the nonstructural proteins nsP2 (a helicase/protease) and nsP4 (an RNA-dependent RNA polymerase) are essential for viral replication. In this study, we evaluated five compounds based on the isatin scaffold: one parent isatin molecule and four synthetic derivatives (ID11–ID14) functionalized with semicarbazone or thiosemicarbazone groups. Cytotoxicity assays confirmed low toxicity for all compounds, with CC₅₀ values above 500 µM. Using a CHIKV replicon model in BHK-CHIKV-NCT cells, compounds ID13 and ID14 significantly reduced EGFP fluorescence, indicating strong inhibition of viral replication. Infectious particle assays supported these results, with all compounds displaying dose-dependent antiviral effects and EC₅₀ values between 20 and 33.6 µM. No significant reduction in viral entry was observed in entry inhibition assays, suggesting that the compounds act post-entry by targeting replication. Molecular docking simulations revealed a predicted propensity of all compounds to interact with important residues of nsP2 and nsP4. Notably, compound ID14 showed the strongest predicted affinity for both enzymes, while compound ID13 demonstrated the highest antiviral efficacy in vitro. These findings highlight isatin derivatives as promising candidates for CHIKV antiviral development and support further exploration of dual-target strategies focusing on viral replication proteins.
- 20 January 2026
- Published by MDPI AG in Preprints.org
Open AccessHydrazone-Isatin Derivatives as Antivirals Against Chikungunya Virus: Insights From Biological and Computational Studies
Chikungunya virus (CHIKV), a re-emerging arbovirus of the Alphavirus genus, causes acute febrile illness often followed by persistent polyarthritis or arthralgia. Due to its rapid transmission and the absence of approved antivirals or licensed vaccines, there is an urgent need for effective therapeutic strategies. Among potential antiviral targets, the nonstructural proteins nsP2 (a helicase/protease) and nsP4 (an RNA-dependent RNA polymerase) are essential for viral replication. In this study, we evaluated five compounds based on the isatin scaffold: one parent isatin molecule and four synthetic derivatives (ID11–ID14) functionalized with semicarbazone or thiosemicarbazone groups. Cytotoxicity assays confirmed low toxicity for all compounds, with CC₅₀ values above 500 µM. Using a CHIKV replicon model in BHK-CHIKV-NCT cells, compounds ID13 and ID14 significantly reduced EGFP fluorescence, indicating strong inhibition of viral replication. Infectious particle assays supported these results, with all compounds displaying dose-dependent antiviral effects and EC₅₀ values between 20 and 33.6 µM. No significant reduction in viral entry was observed in entry inhibition assays, suggesting that the compounds act post-entry by targeting replication. Molecular docking simulations revealed a predicted propensity of all compounds to interact with important residues of nsP2 and nsP4. Notably, compound ID14 showed the strongest predicted affinity for both enzymes, while compound ID13 demonstrated the highest antiviral efficacy in vitro. These findings highlight isatin derivatives as promising candidates for CHIKV antiviral development and support further exploration of dual-target strategies focusing on viral replication proteins.